Clinical Trial Search

Primary: Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Equivalence: Per-Protocol Population) — 1.981; 1.817 score on scale

Primary: Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12: Active Comparator Phase/Efficacy Phase — 58.12; 83.36; 87.17; 23.49 milliliter — p=0.0001

Primary: Adjusted Rate of Moderate or Severe Exacerbations — 1.08; 1.07; 1.42; 1.24 Moderate or Severe Exacerbations — p=<0.0001

Primary: Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24 — 63; 63 percentage of participants

Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants

Primary: Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference — 66; 71; 6; 5 Participants

Primary: Primary Efficacy Analysis of Overall Response Rate ( ORR) of MYL-1402O as Compared to Avastin — 140; 144; 197; 190 Participants

Primary: Progression Free Survival (PFS) — 21.8; 35.3 months — p=0.073

Primary: Oral Disposition (Insulin Sensitivity-insulin Secretion) Index — 471; 311; 503; 395 index score — p=<0.02

Primary: The Time-normalized Number of Hereditary Angioedema Attacks — 0.04; 0.02; 0.12; 0.13 attacks/day — p=< 0.001

Primary: Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours — 9.1; 9.2; 4.4; 5.1 Units on a scale — p=0.12

Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.63; 0.21; 1.25; 0.70 score on a scale

Primary: Preterm Birth <35 Weeks Gestation — 66; 122 Participants

Primary: Rates of HIV Seroconversion — 17; 33 Infections/ 100 person-years

Primary: Gender Distribution of the Patients — 19; 21; 11; 9 Participants